Research Article

Assessment of Toxicity and Therapeutic Effects of Goose Bone in a Rat Model

Md. Yousuf Ali,1 Alamgir Kabir,1 Shahad Saif Khandker,1 Tareq Hossan,1 Md. Salman Shakil,1 Md. Aminul Islam,1 Md. Ashraful Hasan,1 Md. Sakib Hossen,1 Siew Hua Gan2 and Md. Ibrahim Khalil1

1Laboratory of Preventive and Integrative Biomedicine, Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh
2School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor, Malaysia

Correspondence should be addressed to Siew Hua Gan; gan.siewhua@monash.edu and Md. Ibrahim Khalil; drmikhali@gmail.com

Received 17 December 2018; Accepted 7 October 2019; Published 29 October 2019

Copyright © 2019 Md. Yousuf Ali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Goose bone is traditionally used in the treatment of many ailments including in bone fracture. The aim of the present study was to evaluate the subacute toxicity of goose bone in a rat model by investigating some hematological and biochemical parameters in rats. Subsequently, a histopathological study was performed to confirm the presence of pathological lesions in the rat’s vital organs including the liver, kidney, heart, brain, pancreas, lung, spleen, and stomach. Adult Wistar rats were divided into four groups (n = 8) and were orally administrated with three doses (30, 60, and 120 mg/kg) of goose bone once daily for 21 days as compared to control animals (received only drinking water). Goose bone did not cause any significant changes on body weight, relative organ weight, and percentage water content at any of the administered doses. There were also no significant alterations in hematological parameters seen. All three doses administered significantly reduced the triglyceride levels as well as the atherogenic index of plasma (AIP). Animals treated with 120 mg/kg doses had significantly reduced alkaline phosphatase (ALP) activity as compared to the control group. There was no significant alteration on other serum biochemical parameters seen. Additionally, histopathological findings confirmed that there was no inflammatory, necrotic, or other toxicological feature seen for all three doses. It is concluded that goose bone is nontoxic and is safe for consumption besides having the potential to be investigated for the treatment of high triglycerides or liver-related disorder.

1. Introduction

From ancient times, various traditional drugs have been utilized in the treatment of several chronic diseases not only for curing but also for prevention of diseases. Goose bone is a traditional remedy utilized in Malay traditional medicine for several years. It has been widely applied for both external and internal complications, especially in the treatment of fractured bones. Nutritionally, goose bone is rich in protein (35%), carbohydrate (6%), fat (11%), and dietary fiber (5%). Additionally, there is also high calcium (14.6%) content with some other essential minerals including sodium (0.41%), potassium (0.14%), and iron (0.004%) identified. The folklore claims on its use may be substantiated by the fact that calcium is an important mineral for the bones, joints, nerve, and muscle [1–3].

Besides bone fractures, it is also believed that regular consumption of goose bone can boost the immune system. Goose bone is traditionally applied to ameliorate fever, particularly in children. Nowadays, goose bone is processed into powder and is inserted into capsules which are used for treatment. Nevertheless, although goose bone treatment is very popular in folk medicine, there are no scientific data to support its use or to evaluate its toxic effects. Therefore, the aim of this study is to assess the possible toxic effect of goose bone in a rat model by investigating the biochemical, hematological, and histopathological parameters.
2. Materials and Methods

2.1. Chemicals and Reagents. Ketamine hydrochloride injection was purchased from Popular Pharmaceuticals Ltd., Dhaka, Bangladesh. All chemicals and reagents used were of analytical grade.

2.2. Preparation of Goose Bone. The geese (Anserinae anserine) were reared under a tropical environment, in a farmhouse located in Pasir Mas, Kelantan, Malaysia. The geese were fed with mixtures of bran, inner husk of grain, sago (starchy food in hard white grains), vegetables, and rice. The geese were allowed water ad libitum. The geese were ready to be slaughtered based on an Islamic law or "halal" manner when they were one year old. Animals of both genders were used, as long as they have reached the optimum age and appeared to be of an average size of an adult goose.

Then, the geese were slaughtered and the bones were separated from the meat. For powder preparation, only the bones were used. The bones (except for the head and the feet) were burned, crushed, and grinded until it became a fine powder and the color turned blackish. Goose bone powder was prepared in a dry environment to avoid fungal growth and oxidation. Subsequently, the powder was inserted into hard-shelled capsules purchased from pharmacies and was packed in a plastic bottle together with a silica gel substance to preserve it. The capsules have been patented (PI2017701257).

2.3. Experimental Animals. Adult Wistar rats of both sexes (150 to 250 g) at 16–18 weeks were utilized. Animals were bred and reared in the animal house at the Department of Biochemistry and Molecular Biology, Jahangirnagar University, at a constant temperature (23 ± 2°C) and humidity (44% to 56%). The rats were kept in sterile plastic cages containing soft wood-chip bedding and were exposed to a natural 12 h day-night cycle. The rats were allowed free supply of water and a standard laboratory pellet diet. The experimental protocol was approved by the Biosafety, Biosecurity and Ethical Committee of Jahangirnagar University, Savar, Dhaka, Bangladesh (ethical number: BBEC,JU/M2019 (7) 4) which was in agreement with the internationally established principles of the US guidelines.

2.4. Experimental Design. The rats (n = 32) were familiarized to the lab environment 7 days before experimentation. The animals were allotted into four groups (n = 8 rats each) with a balance mix of gender [4].

Group A (normal control): rats were given a normal diet and water ad libitum.

Group B (treatment 1): rats administered with goose bone (30 mg/kg) dissolved in normal saline for 21 days (again, all rats were given a normal diet and water ad libitum).

Group C (treatment 2): rats administered with goose bone (60 mg/kg) dissolved in normal saline for 21 days (again, all rats were given a normal diet and water ad libitum).

Group D (treatment 3): rats administered with goose bone (120 mg/kg) dissolved in normal saline for 21 days (again, all rats were given a normal diet and water ad libitum).

The doses were chosen based on the normal doses taken by human which is approximately 500 mg/day. Calculation of dose in animals based on human dose was done according to the formula as suggested by Reagan-Shaw et al. [5]:

\[ \text{human equivalent dose (mg/kg)} = \text{rat’s dose (mg/kg)} \times \left( \frac{\text{Rat } K_m}{\text{human } K_m} \right), \]

\[ \text{rat’s dose (mg/kg)} = \frac{\text{human equivalent dose (mg/kg)}}{\left( \frac{\text{Rat } K_m}{\text{human } K_m} \right)}, \]

\[ \text{rat’s dose (mg/kg)} = \frac{8.33 \text{ (mg/kg)}}{(6/37)} \left[ \frac{500 \text{ mg}}{60 \text{ kg}} = 8.33 \text{ mg/kg} \right], \]

\[ \text{rat’s dose (mg/kg)} = 51.37 \text{ mg/kg}, \]

where \( K_m \) = correction factor which is estimated by dividing the average body weight (kg) of the species to its body surface area (m\(^2\)). Assuming the average human body weight is 60 kg with a body surface area of 1.62 m\(^2\), \( K_m \) factor for human is calculated by dividing 60 by 1.62, which is 37 (the \( K_m \) value for human is 37 and that for rat is 6).

Based on the calculated dose of 51.37 mg/kg, a rounded value at 60 mg/kg was taken as the middle dose range. From this value, the low dose of 30 mg/kg and a high dose at 120 mg/kg were selected. During the experimental period, the animals were monitored for behavioral changes in their feeding and drinking habits and for some physiological
changes including reduced activity and diarrhea in order to
detect any sign of abnormalities.

2.5. Harvesting of Organs. At the completion of the exper-
iment, the animals were not given any food or water for one
day before ketamine hydrochloride injection (500 mg/kg) [6] via
the intraperitoneal veins. Subsequently, blood (5 mL) was
taken from the inferior vena cava and was transferred to two
tubes. The first tube contained ethylene diamine tetraacetic
acid (EDTA) for hemotological analyses while the second
tube was a plain tube for serum biochemical analyses. The
harvested organs were weighed and were kept in 10% for-
malin for subsequent histopathological examination.

2.6. Measurement of Body and Relative Organ Weights as well
as Percentage Water Content. The animal’s body weights
were measured weekly throughout the experimental period.
For measurement of relative organ weight and percentage of
water content, tissue samples (liver, kidney, heart, lung, spleen,
caecum, pancreas, brain, testes, thymus, caput, stomach, ovary, cower’s gland, and fallopian tube) were
removed and weighed as soon as sacrifice. The relative organ
weight was estimated by dividing the weight of each organ
with the final body weight of each animal based on the
following formula [7]:

\[
\text{relative organ weight (\%)} = \frac{\text{weight of wet organ}}{\text{rat’s body weight}} \times 100. 
\]  

(2)

The percentage of water content was estimated based on
every wet organ by subtracting the dry weight of each organ,
respectively [8].

2.7. Preparation of Serum. Following sacrifice, the blood
samples were transferred to dry test tubes and were left to
coagulate naturally for approximately 30 min. Serum was
yielded following centrifugation (2000 rpm \times 10 min).

2.8. Hematological Parameters. The blood parameters were
analyzed using an automated hematology analyzer (8000i,
Sysmex, Japan) for all groups. These included de-
termination of eosinophils, neutrophils, white blood cells
(WBCs), monocytes, lymphocytes, red blood cells (RBCs),
hemoglobin (HGB), hematocrit (HCT), mean corpuscular
volume(MCV), mean corpuscular hemoglobin (MCH),
platelets (PLT), mean corpuscular hemoglobin concen-
tration (MCHC), erythrocyte sedimentation rate (ESR), red
cell distribution width-standard deviation (RDW-SD), red
cell distribution width-coefficient of variation (RDW-CV),
mean platelets volume (MPV), platelets distribution width
(PDW), platelets larger cell ratio (P-LCR), and procalcit-
onin (PCT).

2.9. Serum Biochemical Analysis. Liver function tests (as-
partate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatase (ALP), γ-glutamyltransferase (GGT),
lactate dehydrogenase (LDH), total protein (TP), total bil-
irubin (TB), albumin (ALB), globulin (GLB), and albumin/
globulin (A/G) ratio; kidney function tests (uric acid, urea,
and creatinine); lipid profiles (triglycerides (TG), total
cholesterol (TC), and high-density lipoprotein cholesterol
(HDL-C)), serum electrolytes including sodium (Na+),
chloride (Cl\textsuperscript{-}), potassium (K\textsuperscript{+}), calcium (Ca\textsuperscript{2+}), magnesium
(Mg\textsuperscript{2+}), and phosphate (PO\textsuperscript{4}\textsuperscript{-}) ions, pancreatic function
tests (the enzymes such as lipase and amylase), and also
glycemic condition such as serum glucose (GLU) con-
centrations were established based on standard tests using
an automated chemistry analyzer (Dimension EXL with
LM Integrated Chemistry System, Siemens Medical Solu-
tions Inc., USA). Another important factor lipid profile such as serum low-density lipoprotein cholesterol
(LDL-C) level was established according to the Friedewald
formula [9]:

\[
\text{LDL-C} = \frac{\text{TC} - \text{HDL-C} - \text{TG}}{5}. 
\]  

(3)

Atherogenic indices including cardiac risk ratio (CRR),
atherogenic index of plasma (AIP), atherogenic coefficient
(AC), and Castelli’s risk index-2 (CRI-2) were estimated
according to the following formulae [10--13]:

\[
\text{CRR} = \frac{\text{TC}}{\text{HDL-C}},
\]

\[
\text{AC} = \frac{(\text{TC} - \text{HDL-C})}{\text{HDL-C}},
\]

\[
\text{AIP} = \log\left(\frac{\text{TG}}{\text{HDL-C}}\right),
\]

\[
\text{CRI-2} = \frac{\text{LDL-C}}{\text{HDL-C}}.
\]  

2.10. Histopathological Findings. The liver, brain, spleen,
lung, stomach, kidney, heart, and pancreas tissue samples
were fixed in formalin (10%) followed by paraffin embedding
fixing. The specimens were sliced into slices of 5 μm
thickness by means of a rotary microtome. The specimens
were then tained using hematoxylin and eosin dye [14].
Photomicrographs were taken by using a normal-spectrum
fluorescence microscope (Olympus DP 72) at 40x magni-
fication. The microscope was connected to a digital camera
(Olympus, Tokyo, Japan). The pathologist who conducted
the histopathological examination was unaware to the

treatment groups.

2.11. Statistical Analysis. The results were expressed as
mean ± standard deviation (SD). Data were evaluated by
using SPSS (version 16.0, IBM Corporation, New York,
USA). Data from the treatment groups were evaluated
against the control by using a one-way ANOVA followed by
Dunnett’s multiple comparison tests where \( p < 0.05 \) was
deemed as statistically significant.
3. Results

3.1. The Effects of Goose Bone on Body Weight, Relative Organ Weight, and Percent Water Content of Rat’s Organs. During the experimental period, rats’ body weight increased gradually although these changes were not significantly different from the first to the third week (Figure 1) as compared to the control. There was also no significant difference in both relative organ weight and percentage of water content of different rat’s organs (Tables 1 and 2).

3.2. The Effects of Goose Bone on the Hematological Parameters. There was no significant difference among the control and treatments groups in terms of hematological parameters (Table 3).

No significant changes were established when all treatment groups were compared against the control group by using one-way ANOVA followed by Dunnett’s multiple comparison tests.

3.3. The Effects of Goose Bone on Serum Biochemical Parameters. Goose bone did not confer any effects on parameters for liver function including ALT, AST, ALP, GGT, LDH activities, and TB levels. In fact, ALP levels were significantly decreased at the highest dose (120 mg/kg) while ALT, AST, TP, ALB, GLB, and A/G which are important biomarkers of liver function remained unchanged at the three dose levels (Figure 2 and Table 4) indicating that goose bone does not affect the function of this major organ and may help to protect against liver damage especially when used in high doses.

The effects of goose bone on the renal function were analyzed by measuring serum urea, uric acid, and creatinine levels and major electrolytes such as Na⁺, K⁺, Cl⁻, Mg²⁺, P, and Ca²⁺ levels (Table 5). All three doses did not significantly affect the biomarkers for renal function or alter body electrolytes levels.

Lipid profiles (TC, TG, HDL-C, and LDL-C) and atherogenic indices (CRR, AC, AIP, and CRI-2) are reliable markers for cardiovascular diseases. Goose bone significantly reduced serum TG levels (Figure 3) and AIP at all three doses (Table 6).

Goose bone did not affect pancreatic function and blood glucose levels where there were no significant changes on the serum amylase, lipase, and glucose levels (Table 7).

3.4. Histopathological Examination. Histopathological examination of the liver, kidney, lung, brain, stomach, pancreas, spleen, and heart did not show any morphological and pathological changes following the administration of goose bone in all three doses (30, 60, and 120 mg/kg) when compared with the control (Figure 4) again confirming its safety on these organs.

4. Discussion

To our knowledge, this is the first study to confirm the safety profile of goose bone. Daily oral administration of goose bone in a rat model at 30, 60, and 120 mg/kg for 21 days did not cause mortality, change in food habit and water intake, body and organ weight, and biochemical findings, confirming that goose bone is safe when administered at these doses. Additionally, there were no histopathological changes in the organs including the liver, kidney, heart, pancreas, stomach, brain, lung, and spleen confirming that goose bone is safe.

Toxic agents are responsible for abnormal metabolic reactions in the body that may alter the growth of animals and cause deposition of water in vital organs like the liver, heart, lung, spleen, brain, kidney, and reproductive organs including the testes, caput, cowper gland (in males), and ovary and fallopian tube (in females) [15]. Therefore, body and relative organ weights as well as percentage water content are important parameters for toxicological studies. In the present study, no significant difference was observed in body and relative organ weights as well as percentage water content were compared with those of the control group during the experimental period indicating that goose bone does not affect these parameters and rats’ homeostasis.

Analysis of hematological parameter is important when assessing physiological and pathological conditions in the body. Deprivation, stress, abnormal body metabolic activities, and response of the body to injury or lesions are closely-related with abnormal findings for hematological parameter [16]. In fact, hematological parameters like RBCs, HGB, HCT, MCV, MCH, MCHC, RDW-SD, and RDW-CV can help to unravel important information about anemic condition and other erythrocyte cell-related disorders such as polycythemia and thalassemia. WBCs and its differential count including neutrophils, lymphocytes, eosinophils, monocytes, and basophils play important roles in the immune system in combating infections where the overproduction of these parameters are important hallmarks of inflammation and stress-related disorders [17, 18]. Platelets and platelet indices including MPV, PDW, and P-LCR are important indicators for early diagnosis of thromboembolic, atherosclerosis, and ischemic heart disease [19–21]. The levels of both ESR and PCT can yield important information about inflammatory condition in the body. In our present study, there were no significant changes in the hematological findings indicating that administration of goose bone causes no toxic effect on the animal’s body.

The liver is the major site for detoxification and elimination of toxic substance from the body. Any foreign substances that may affect the liver function can alter ALT, AST, ALP, GGT, TB, TP, ALB, GLB, and albumin-globulin (A/G) ratio activities [22, 23]. Generally, damage to the parenchymal liver cell is associated with elevation of these enzymes in the blood [24]. ALT and AST are the major intracellular cytoplasmic enzymes where their elevation in the serum indicates some injuries in the liver cells [25]. On the other hand, ALP and GGT are indicators for hepatobiliary damage [26] while AST and LDH, mostly found in the heart, liver, kidney, and skeletal muscle, are indicators of both myocardium and hepatocellular injuries [23]. TB indicates liver injury or necrosis and measures the binding, conjugation, and excretory capacities of the hepatocytes.
Figure 1: The effects of goose bone on body weight (g) gain. Results are expressed as mean ± SD. (n = 8). Nonsignificant changes were found when all treatment groups were compared against the control group (p < 0.05) as determined by one-way ANOVA followed by Dunnett’s multiple comparison tests.

Table 1: The effects of goose bone on relative organ weight.

| Organs       | Control      | 30 mg/kg     | 60 mg/kg     | 120 mg/kg    |
|--------------|--------------|--------------|--------------|--------------|
| Heart        | 0.384 ± 0.01 | 0.359 ± 0.01 | 0.367 ± 0.01 | 0.320 ± 0.02 |
| Kidney       | 0.781 ± 0.07 | 0.807 ± 0.03 | 0.801 ± 0.05 | 0.795 ± 0.07 |
| Lung         | 0.671 ± 0.87 | 0.713 ± 0.14 | 0.657 ± 0.13 | 0.634 ± 0.02 |
| Liver        | 3.732 ± 0.40 | 3.890 ± 0.26 | 3.849 ± 0.11 | 3.742 ± 0.45 |
| Spleen       | 0.226 ± 0.01 | 0.233 ± 0.02 | 0.232 ± 0.01 | 0.211 ± 0.01 |
| Caecum       | 0.276 ± 0.02 | 0.265 ± 0.04 | 0.257 ± 0.04 | 0.255 ± 0.05 |
| Pancreas     | 0.129 ± 0.06 | 0.156 ± 0.04 | 0.172 ± 0.11 | 0.124 ± 0.06 |
| Brain        | 0.864 ± 0.01 | 0.874 ± 0.05 | 0.871 ± 0.07 | 0.829 ± 0.15 |
| Testes       | 0.113 ± 0.09 | 0.121 ± 0.08 | 0.118 ± 0.09 | 0.097 ± 0.06 |
| Thymus       | 0.133 ± 0.01 | 0.149 ± 0.06 | 0.139 ± 0.07 | 0.147 ± 0.05 |
| Caput        | 0.287 ± 0.07 | 0.268 ± 0.09 | 0.254 ± 0.05 | 0.276 ± 0.05 |
| Cowper gland | 0.151 ± 0.01 | 0.159 ± 0.01 | 0.156 ± 0.00 | 0.152 ± 0.01 |
| Stomach      | 0.659 ± 0.03 | 0.630 ± 0.01 | 0.590 ± 0.03 | 0.608 ± 0.02 |
| Ovary        | 0.075 ± 0.03 | 0.077 ± 0.01 | 0.070 ± 0.02 | 0.072 ± 0.03 |
| Fallopian tube | 0.306 ± 0.01 | 0.280 ± 0.01 | 0.282 ± 0.01 | 0.270 ± 0.01 |

Results are expressed as mean ± SD (n = 8). Nonsignificant changes were found when all treatment groups were compared against the control group (p < 0.05) as determined using one-way ANOVA followed by Dunnett’s multiple comparison tests.

Table 2: The effects of goose bone on the percentage of water content of different organs.

| Organs           | Control      | 30 mg/kg     | 60 mg/kg     | 120 mg/kg    |
|------------------|--------------|--------------|--------------|--------------|
| Heart            | 52.90 ± 1.13 | 55.23 ± 0.83 | 53.95 ± 2.42 | 52.84 ± 1.61 |
| Kidney           | 52.01 ± 5.55 | 52.32 ± 8.15 | 51.50 ± 5.16 | 53.93 ± 3.76 |
| Lung             | 61.03 ± 1.21 | 61.84 ± 3.45 | 61.87 ± 2.73 | 59.75 ± 1.62 |
| Liver            | 60.63 ± 4.47 | 54.40 ± 5.11 | 54.87 ± 1.24 | 53.71 ± 1.38 |
| Spleen           | 47.75 ± 0.67 | 50.23 ± 2.38 | 51.38 ± 3.38 | 46.59 ± 1.85 |
| Caecum           | 65.55 ± 1.12 | 63.52 ± 1.92 | 64.58 ± 1.43 | 63.82 ± 1.73 |
| Pancreas         | 41.68 ± 8.65 | 40.26 ± 2.81 | 38.27 ± 1.32 | 37.81 ± 0.37 |
| Brain            | 57.78 ± 7.46 | 53.74 ± 5.82 | 45.51 ± 1.80 | 32.37 ± 10.58 |
| Testes           | 41.53 ± 6.30 | 55.32 ± 3.87 | 50.13 ± 1.67 | 31.47 ± 3.49 |
| Thymus           | 59.58 ± 1.12 | 54.81 ± 1.01 | 58.22 ± 1.13 | 55.71 ± 1.45 |
| Caput            | 61.30 ± 1.89 | 65.24 ± 2.00 | 64.22 ± 1.65 | 64.85 ± 1.91 |
| Cowper gland     | 67.68 ± 1.19 | 62.15 ± 2.68 | 66.21 ± 1.90 | 65.98 ± 2.07 |
| Stomach          | 60.91 ± 2.45 | 58.75 ± 1.95 | 58.15 ± 4.21 | 56.26 ± 1.23 |
| Ovary            | 56.65 ± 2.76 | 56.34 ± 1.59 | 54.20 ± 1.39 | 57.14 ± 1.87 |
| Fallopian tube   | 39.01 ± 0.01 | 29.88 ± 0.01 | 28.13 ± 0.01 | 35.20 ± 0.01 |

Results are expressed as mean ± SD (n = 8). Nonsignificant changes were found when all treatment groups were compared against the control group (p < 0.05) as determined using one-way ANOVA followed by Dunnett’s multiple comparison tests.

Kidneys. Therefore, increase in their serum levels indicates functional damage to kidneys [29, 30]. In our study, there were no significant changes in these renal biomarkers following administration of low to highest dose ranges of goose bone, indicating that goose bone is not toxic to the kidneys as further confirmed by histopathological observations of the kidney tissues.

Serum lipid profile is measured to predict hyperlipoproteinemia, triglyceridemia, liver obstruction, fatty liver disease, and pancreatitis [31, 32]. Elevated levels of plasma triglyceride level are an important risk factor for cardiovascular disease [33] and are related to hypertension [34], diabetes mellitus, and obesity [35]. In fact, high plasma total cholesterol levels are linked to the development of atherosclerosis and other cardiovascular-related disease [36]. In addition, low HDL-C and high LDL-C are imperative predictors for cardiovascular disease [37] where high HDL-C shows a protective role by enhancing cholesterol transport via collection of excess cholesterol from peripheral tissue. On the other hand, atherogenic indices (CRR, ACC, and CRI-2) are derived from lipid panels where the increase in the atherogenic indices is associated with the development of cardiovascular diseases. In our study, goose bone significantly reduced serum TG levels and AIP at all doses administered while other parameters of lipid profile and atherogenic indices remain unchanged. In some previous reports, natural products that are high in omega-3 fatty acids have been reported to reduce TG levels. For example, Shearer et al. suggested that fish oil containing omega-3 fatty acid can reduce TG level [38] as also with goose bone which is high in lipid content that is healthy to the body. Similarly, since AIP is a logarithmic ratio of TG and HDL-C, when TG levels are reduced, AIP is also decreased as seen in this case.
Table 3: The effects of goose bone on the hematological parameters in whole blood.

| Hematological parameters | Control | 30 mg/kg | 60 mg/kg | 120 mg/kg |
|--------------------------|---------|----------|----------|-----------|
| WBC (×10^9/L)            | 6.15 ± 1.31 | 6.61 ± 0.71 | 6.40 ± 1.30 | 4.87 ± 1.03 |
| NEUT (%)                 | 15.75 ± 1.89 | 14.25 ± 2.50 | 15.75 ± 1.89 | 19.75 ± 3.59 |
| LYMPH (%)                | 81.25 ± 2.87 | 84.25 ± 2.63 | 81.25 ± 2.87 | 76.75 ± 3.86 |
| Mono (%)                 | 1.65 ± 0.39 | 1.35 ± 0.17 | 1.65 ± 0.39 | 1.28 ± 0.22 |
| Eo (%)                   | 1.02 ± 0.36 | 1.30 ± 0.29 | 1.18 ± 0.35 | 1.05 ± 0.13 |
| RBC (×10^12/L)           | 6.12 ± 2.36 | 6.11 ± 2.36 | 6.12 ± 2.36 | 7.70 ± 0.49 |
| HGB (g/dL)               | 13.80 ± 1.11 | 13.80 ± 1.17 | 13.80 ± 1.12 | 14.40 ± 0.74 |
| ESR (mm)                 | 3.40 ± 0.11 | 4.10 ± 0.31 | 3.90 ± 0.42 | 4.00 ± 0.34 |
| HCT (%)                  | 35.85 ± 13.85 | 35.85 ± 13.85 | 35.85 ± 13.85 | 44.35 ± 2.79 |
| MCV (fL)                 | 58.70 ± 1.24 | 58.70 ± 1.24 | 58.70 ± 1.24 | 57.63 ± 1.31 |
| MCH (pg)                 | 18.70 ± 0.76 | 18.70 ± 0.76 | 18.70 ± 0.76 | 18.70 ± 0.26 |
| MCHC (g/dL)              | 31.88 ± 1.23 | 31.88 ± 1.23 | 31.88 ± 1.23 | 32.50 ± 0.85 |
| PLT (×10^9/L)            | 692.00 ± 267.70 | 692.00 ± 267.71 | 692.00 ± 267.71 | 803.75 ± 86.32 |
| RDW-SD (fL)              | 27.70 ± 2.32 | 27.70 ± 2.32 | 27.70 ± 2.32 | 27.53 ± 3.12 |
| RDW-CV (%)               | 14.25 ± 2.18 | 14.25 ± 2.18 | 14.25 ± 2.18 | 15.28 ± 2.46 |
| PDW (fL)                 | 8.80 ± 0.27 | 8.80 ± 0.27 | 8.80 ± 0.27 | 8.93 ± 0.33 |
| MPV (fL)                 | 8.40 ± 0.54 | 8.40 ± 0.51 | 8.40 ± 0.51 | 8.18 ± 0.26 |
| P-LCR (%)                | 12.80 ± 2.80 | 12.80 ± 2.79 | 12.80 ± 2.79 | 11.30 ± 1.90 |
| PCT (%)                  | 0.58 ± 0.21 | 0.58 ± 0.21 | 0.58 ± 0.21 | 0.66 ± 0.09 |

Results are expressed as mean ± SD (n = 8). HGB: hemoglobin, HCT: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, PLT: platelets, RDW-SD: red cell distribution width-standard deviation, RDW-CV: red cell distribution width-coefficient of variation, PDW-CV: platelets distribution width, ESR: erythrocyte sedimentation rate, MPV: mean platelets volume, P-LCR: platelets larger cell ratio, and PCT: procalcitonin.

Figure 2: The effects of goose bone on serum hepatic marker enzymes. Results are expressed as mean ± SD (n = 8). * denotes level of significant difference when compared to the control group as determined using a one-way ANOVA followed by Dunnett’s multiple comparison tests.

Table 4: The effects of goose bone on serum total bilirubin (TB), total protein (TP), albumin (ALB), globulin (GLB), and albumin/globulin (A/G) ratio.

| Biochemical parameters | Control | 30 mg/kg | 60 mg/kg | 120 mg/kg |
|------------------------|---------|----------|----------|-----------|
| TB (mg/dL)             | 0.20 ± 0.07 | 0.17 ± 0.04 | 0.20 ± 0.07 | 0.22 ± 0.04 |
| TP (g/L)               | 5.45 ± 0.33 | 5.48 ± 0.27 | 5.35 ± 0.44 | 5.34 ± 0.38 |
| ALB (g/L)              | 2.70 ± 0.14 | 2.66 ± 0.14 | 2.56 ± 0.30 | 2.71 ± 0.21 |
| GLB (g/L)              | 2.75 ± 0.18 | 2.82 ± 0.15 | 2.79 ± 0.23 | 2.63 ± 0.17 |
| A/G                    | 0.98 ± 0.01 | 0.94 ± 0.04 | 0.92 ± 0.10 | 1.02 ± 0.02 |

Results are expressed as mean ± SD (n = 6). No significant changes were established when all treatment groups were compared against the control group by using one-way ANOVA followed by Dunnett’s multiple comparison tests.

Another highlight of our research was the histopathological study that further confirmed the nontoxic effect of goose bone. Toxic substances cause degenerative necrosis of hepatocytes, vacuolization of the hepatic lobules [43], degeneration of the kidney glomeruli with inflammatory infiltrates [44], massive separation of cardiac muscle necrotic damage to the myocytes of the heart tissue [45] and islets of Langerhans of pancreas [46], neuronal degeneration of brain [47], damage of alveoli of lung [48], inflammation of the mucous layers of stomach [49], and damage of the hematopoietic and lymphoid elements of spleen [50]. The histopathological findings of the major organs provide a further strong support on its safety. Overall, our study confirms that goose bone is nontoxic, safe, and beneficial to some extent (especially on the liver and hematological profiles) to be consumed at the normal doses taken in humans.

Our study has some limitations. Since the effects of goose bone were investigated only for 21 days, its subchronic and...
chronic effects were not investigated. Therefore, future studies should be conducted to investigate the long-term effects of goose bone. Additionally, the dose can be increased based on the Organization for Corporation and Development (OECD) guideline in order to have a more rigorous test. Finally, the use of Hematoxylin-Eosin-Saffron

Table 5: The effects of goose bone on serum renal markers.

| Biochemical parameters | Control   | 30 mg/kg | 60 mg/kg | 120 mg/kg |
|------------------------|-----------|----------|----------|-----------|
| Creatinine (mmol/L)    | 0.35 ± 0.02 | 0.37 ± 0.04 | 0.39 ± 0.03 | 0.36 ± 0.01 |
| Urea (mmol/L)          | 35.10 ± 1.64 | 28.20 ± 0.51 | 39.72 ± 5.07 | 36.81 ± 6.23 |
| UA (mmol/L)            | 0.45 ± 0.07 | 0.43 ± 0.09 | 0.29 ± 0.14 | 0.33 ± 0.11 |
| Na⁺ (mmol/L)           | 138.25 ± 6.49 | 141.25 ± 0.82 | 141.00 ± 3.67 | 145.50 ± 4.97 |
| K⁺ (mmol/L)            | 3.72 ± 0.31 | 4.02 ± 1.23 | 4.22 ± 0.64 | 4.62 ± 0.92 |
| Cl⁻ (mmol/L)           | 101.00 ± 5.74 | 104.75 ± 3.89 | 104.25 ± 2.58 | 107.00 ± 3.53 |
| PO₄³⁻ (mmol/L)         | 8.20 ± 0.75 | 9.45 ± 1.67 | 8.61 ± 1.47 | 8.30 ± 1.06 |
| Ca²⁺ (mmol/L)          | 10.26 ± 0.78 | 11.03 ± 1.09 | 11.05 ± 1.12 | 11.47 ± 0.52 |
| Mg²⁺ (mmol/L)          | 0.75 ± 0.06 | 0.69 ± 0.07 | 0.80 ± 0.11 | 0.78 ± 0.08 |

Results are expressed as mean ± SD (n = 8). * denotes level of significant difference when compared to the control group as determined using one-way ANOVA followed by Dunnett’s multiple comparison tests.

Table 6: The effects of goose bone on atherogenic indices.

| Biochemical parameters | Control   | 30 mg/kg | 60 mg/kg | 120 mg/kg |
|------------------------|-----------|----------|----------|-----------|
| CRR                    | 2.21 ± 0.17 | 1.96 ± 0.26 | 2.02 ± 0.30 | 1.86 ± 0.34 |
| ACC                    | 1.20 ± 0.17 | 0.96 ± 0.26 | 1.02 ± 0.30 | 0.86 ± 0.34 |
| AIP                    | 0.25 ± 0.08 | 0.21 ± 0.01* | 0.20 ± 0.07* | 0.18 ± 0.02* |
| CRI-2                  | 0.84 ± 0.22 | 0.75 ± 0.28 | 0.83 ± 0.28 | 0.64 ± 0.30 |

Results are expressed as mean ± SD (n = 8). * denotes level of significant difference when compared to the control group as determined using a one-way ANOVA followed by Dunnett’s multiple comparison tests.

Table 7: The effects of goose bone on pancreatic function.

| Biochemical parameters | Control   | 30 mg/kg | 60 mg/kg | 120 mg/kg |
|------------------------|-----------|----------|----------|-----------|
| Amylase (U/L)          | 2145.25 ± 403.83 | 2080.00 ± 565.73 | 2196.00 ± 615.50 | 2070.50 ± 388.30 |
| Lipase (U/L)           | 27.13 ± 2.61 | 29.43 ± 2.09 | 24.56 ± 2.91 | 25.86 ± 3.60 |
| Glucose (mmol/L)       | 10.27 ± 0.88 | 10.59 ± 0.47 | 9.47 ± 1.11 | 9.64 ± 1.54 |

Results are expressed as mean ± SD (n = 8). No significant changes were found when all treatment groups were compared with the control group (p < 0.05) as determined by using one-way ANOVA followed by Dunnett’s multiple comparison tests.
may be more ideal in histopathological analysis since saffron stains collagen fibers in the tissues besides contributing to complete removal of eosin.

5. Conclusion

Goose bone is nontoxic and is safe for consumption at the investigated doses. Oral administration of goose bone up to 120 mg/kg did not significantly affect body weight, relative organ weight profile, and percentage water content of vital organs as well as physiological, hematological, and biochemical abnormalities over the three-week treatment period. The histopathological findings on the major organs further confirm its safety. Additionally, goose bone may ameliorate high triglyceride and ALP-related disorders.
Data Availability

The data used to support the findings of this study are enclosed within the article. Additional data are accessible from the corresponding author upon request.

Conflicts of Interest

The goose bone capsules studied in this research were provided by Star Goose Enterprise, who hold a patent (PI2017701257) and provided financial support.

Acknowledgments

We would like to acknowledge Madam Roxhana Omar, Managing Director, Star Goose Enterprise, Pasir Mas, Kelantan, Malaysia, for providing financial support and goose bone capsules used in this study.

References

[1] A. Flynn, "The role of dietary calcium in bone health," *Proceedings of the Nutrition Society*, vol. 62, no. 4, pp. 851–858, 2003.

[2] G. E. Gibson and C. Peterson, "Calcium and the aging nervous system," *Neurobiology of Aging*, vol. 8, no. 4, pp. 329–343, 1987.

[3] J. Z. Ilich and J. E. Kerstetter, "Nutrition in bone health revisited: a story beyond calcium," *Journal of the American College of Nutrition*, vol. 19, no. 6, pp. 715–737, 2000.

[4] M. Ali et al., "Antioxidant potential, subacute toxicity, and beneficial effects of methanolic extract of pomelo (Citrus grandis L. Osbeck) in long evan rats," *Journal of Toxicology*, vol. 2019, p. 12, 2019.

[5] S. Reagan-Shaw, M. Nihal, and N. Ahmad, "Dose translation from animal to human studies revisited," *The FASEB Journal*, vol. 22, no. 3, pp. 659–661, 2008.

[6] D. Ringer, "Humoral and clinical biochemistry," in *The Laboratory Rat*, pp. 105–121, Academic Press, Cambridge, MA, USA, 1979.

[7] Z. Liu et al., "The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats," *Toxicology*, vol. 203, no. 1–3, pp. 139–143, 2004.

[8] J. M. Peters and E. M. Boyd, "Organ weights and water levels of the rat following reduced food intake," *The Journal of Nutrition*, vol. 90, no. 4, pp. 354–360, 1966.

[9] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge," *Clinical Chemistry*, vol. 18, no. 6, pp. 499–502, 1972.

[10] D. M. Martyrosyan, L. A. Miroshnichenko, S. N. Kulakova, A. V. Pogojeva, and V. I. Zoloedov, "Amaranth oil application for coronary heart disease and hypertension," *Lipids in Health and Disease*, vol. 6, no. 1, p. 1, 2007.

[11] A. Brehm, "Relationship between serum lipoprotein ratios and insulin resistance in obesity," *Clinical Chemistry*, vol. 50, no. 12, pp. 2316–2322, 2004.

[12] M. Dobiašová, "Atherogenic index of plasma [log (triglycerides/HDL-cholesterol)]: theoretical and practical implications," *Clinical Chemistry*, vol. 7, pp. 1113–1115, 2004.

[13] W. P. Castelli, R. D. Abbott, and P. M. McNamara, "Summary estimates of cholesterol used to predict coronary heart disease," *Circulation*, vol. 67, no. 4, pp. 730–734, 1983.

[14] H. M. Carleton, R. A. B. Drury, and E. A. Wallington, *Carleton’s Histological Technique*, Oxford University Press, Cary, NC, USA, 1980.

[15] E. Dybing et al., "Hazard characterisation of chemicals in food and diet: dose response, mechanisms and extrapolation issues," *Food and Chemical Toxicology*, vol. 40, no. 2-3, pp. 237–282, 2002.

[16] A. Dal Bosco, Z. Gerencsér, Z. Szendrő et al., "Effect of dietary supplementation of Spirulina (Arthospira platensis) and Thyme (Thymus vulgaris) on rabbit meat appearance, oxidative stability and fatty acid profile during retail display," *Meat Science*, vol. 96, no. 1, pp. 114–119, 2014.

[17] R. Ross, "Atherosclerosis—an inflammatory disease," *New England Journal of Medicine*, vol. 340, no. 2, pp. 115–126, 1999.

[18] E. Tousson, M. El-Moghazy, and E. El-Atrsh, "The possible effect of diets containing Nigella sativa and Thymus vulgaris on blood parameters and some organs structure in rabbit," *Toxicology and Industrial Health*, vol. 27, no. 2, pp. 107–116, 2011.

[19] M. Gawaz, H. Langer, and A. E. May, "Platelets in inflammation and atherogenesis," *Journal of Clinical Investigation*, vol. 115, no. 12, pp. 3378–3384, 2005.

[20] E. Vagdatli, E. Gournari, E. Lazaridou, E. Katsibourlia, F. Tsikopoulou, and I. Labrianou, "Platelet distribution width: a simple, practical and specific marker of activation of coagulation," *Hippokratia*, vol. 14, no. 1, pp. 28–32, 2010.

[21] A. Ihara, T. Kawamoto, K. Matsumoto, S. Shouno, T. Morimoto, and Y. Noma, "Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease," *Pathophysiology of Haemostasis and Thrombosis*, vol. 35, no. 5, pp. 388–391, 2006.

[22] F. M. El-Demerdash, "Antioxidant effect of vitamin E and selenium on lipid peroxidation, enzyme activities and biochemical parameters in rats exposed to aluminium," *Journal of Trace Elements in Medicine and Biology*, vol. 18, no. 1, pp. 113–121, 2004.

[23] P. L. Wolf, "Biochemical diagnosis of liver disease," *Indian Journal of Clinical Biochemistry*, vol. 14, no. 1, pp. 59–90, 1999.

[24] N. Anderson and J. Borlak, "Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis," *Pharmacological Reviews*, vol. 60, no. 3, pp. 311–357, 2008.

[25] B. R. Thapa and A. Walia, "Liver function tests and their interpretation," *The Indian Journal of Pediatrics*, vol. 74, no. 7, pp. 663–671, 2007.

[26] A. Singh, T. K. Bhat, and O. P. Sharma, "Clinical biochemistry of hepatotoxicity," *Journal of Clinical Toxicology*, vol. 4, no. 1, pp. 1–19, 2011.

[27] P. T. Giboney, "Mildly elevated liver transaminase levels in the asymptomatic patient," *American Family Physician*, vol. 71, no. 6, pp. 1105–1110, 2005.

[28] E. M. Tanvir, R. Afroz, M. A. Z. Chowdhury et al., "Honey has a protective effect against chlorpyrifos-induced toxicity on lipid peroxidation, diagnostic markers and hepatic histopathology," *European Journal of Integrative Medicine*, vol. 7, no. 5, pp. 525–533, 2015.

[29] A. Monira, K. El, and Z. Naima, "Evaluation of protective and antioxidant activity of thyme (Thymus vulgaris) extract on paracetamol-induced toxicity in rats," *Australian Journal of Basic and Applied Sciences*, vol. 6, no. 7, pp. 467–474, 2012.
[30] W. Van Biesen, R. Vanholder, and N. Lameire, “Defining acute renal failure: RIFLE and beyond: table 1,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1314–1319, 2006.

[31] M. Ali, S. Paul, E. M. Tanvir et al., “Antihyperglycemic, antidiabetic, and antioxidant effects of Garcinia pedunculata in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 2979760, 15 pages, 2017.

[32] C. Matteoni, Z. Younossi, T. Gramlich, N. Boparai, Y. Liu, and A. Mccullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999.

[33] P. McBride, “Triglycerides and risk for coronary artery disease,” Current Atherosclerosis Reports, vol. 10, no. 5, pp. 386–390, 2008.

[34] J. Zicha, J. Kuneˇ s, and M.-A. Devynck, Abnormalities of Membrane Function and Lipid Metabolism in Hypertension: A Review, Oxford University Press, Oxford, UK, 1999.

[35] G. Shen, “Lipid disorders in diabetes mellitus and current management,” Current Pharmaceutical Analysis, vol. 3, no. 1, pp. 17–24, 2007.

[36] O. Ademuyiwa, R. Ugbaja, F. Idumebor, and O. Adebawo, “Plasma lipid profiles and risk of cardiovascular disease in occupational lead exposure in Abeokuta, Nigeria,” Lipids in Health and Disease, vol. 4, no. 1, p. 19, 2005.

[37] A. H. Lichtenstein, L. J. Appel, M. Brands et al., “Diet and lifestyle recommendations revision 2006,” Circulation, vol. 114, no. 1, pp. 82–96, 2006.

[38] G. C. Shearer, O. V. Savinova, and W. S. Harris, “Fish oil—how does it reduce plasma triglycerides?,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, vol. 1821, no. 5, pp. 843–851, 2012.

[39] J. L. Rosenblum, “Serum lipase activity is increased in disease states other than acute pancreatitis: amylase revisited,” Clinical Chemistry, vol. 37, no. 3, pp. 315-316, 1991.

[40] P.-A. Clavien, S. Burgan, and A. R. Moossa, “Serum enzymes and other laboratory tests in acute pancreatitis,” British Journal of Surgery, vol. 76, no. 12, pp. 1234–1243, 1989.

[41] M. Ventrucci, R. Pezzilli, L. Gullo, L. Platé, G. Sprovieri, and L. Barbara, “Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease,” Digestive Diseases and Sciences, vol. 34, no. 1, pp. 39–45, 1989.

[42] K. G. M. M. Alberti, P. Z. Zimmet, and WHO Consultation, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998.

[43] L. Mannelli, S. Kim, C. H. Hajdu, J. S. Babb, T. W. I. Clark, and B. Taouli, “Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver,” American Journal of Roentgenology, vol. 193, no. 4, pp. 1044–1052, 2009.

[44] C. Langenberg, S. M. Bagshaw, C. N. May, and R. Bellomo, “The histopathology of septic acute kidney injury: a systematic review,” Critical Care, vol. 12, no. 2, p. R38, 2008.

[45] M. C. Fishbein, D. Maclean, and P. R. Maroko, “The histopathologic evolution of myocardial infarction,” Chest, vol. 73, no. 6, pp. 843–849, 1978.

[46] M. F. McLoughlin, R. N. Nelson, J. I. McCormick, H. M. Rowley, and D. B. Bryson, “Clinical and histopathological features of naturally occurring pancreas disease in farmed Atlantic salmon, Salmo salar L.,” Journal of Fish Diseases, vol. 25, no. 1, pp. 33–43, 2002.

[47] W. D. Dietrich, O. Alonso, R. Busto, M. Y.-T. Globus, and M. D. Ginsberg, “Post-traumatic brain hypothermia reduces histopathological damage following concussive brain injury in the rat,” Acta Neuropathologica, vol. 87, no. 3, pp. 250–258, 1994.

[48] S. Sugaar and H. H. Leveen, “A histopathologic study on the effects of radiofrequency thermotherapy on malignant tumors of the lung,” Cancer, vol. 43, no. 2, pp. 767–783, 1979.

[49] K. Terao, E. Ito, Y. Sakamaki, K. Igarashi, A. Yokoyama, and T. Yasumoto, “Histopathological studies of experimental marine toxin poisoning. II. The acute effects of maitotoxin on the stomach, heart and lymphoid tissues in mice and rats,” Toxicon, vol. 26, no. 4, pp. 395–402, 1988.

[50] A. W. Suttie, “Histopathology of the spleen,” Toxicologic Pathology, vol. 34, no. 5, pp. 466–503, 2006.